Time limited offer for new users ▶ Get up to 3 months free

Serving leading biopharmaceutical companies globally:

Baxter
Mallinckrodt
Moodys
McKinsey
Medtronic
Johnson and Johnson

Last Updated: February 7, 2023

CLINICAL TRIALS PROFILE FOR ACTHAR GEL


✉ Email this page to a colleague

« Back to Dashboard

▶ Start for $1
Remove trial restrictions


All Clinical Trials for Acthar Gel

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00805753 ↗ Dose-Finding Pilot Study of ACTH in Patients With Idiopathic Membranous Nephropathy Completed Mallinckrodt Phase 1 2009-01-01 This pilot study is aimed at demonstrating the effectiveness of ACTH (H.P. Acthar Gel) on the lipid profile and proteinuria in participants with MN. ACTH or adrenocorticotrophin is a hormone produced by the pituitary gland (a gland at the base of your brain) that is involved in stimulating your adrenal glands to secrete a number of steroid products (e.g. cortisol, aldosterone, corticosterone, and others) that are important in keeping you alive. The drug used in this study has been approved by the Food and Drug Administration (FDA) for routine clinical use in the treatment of patients with proteinuria and patients with idiopathic nephrotic syndrome such as idiopathic MN. However, the most adequate dose to use has not been adequately assessed. This is the reason for conducting this research study.
NCT00805753 ↗ Dose-Finding Pilot Study of ACTH in Patients With Idiopathic Membranous Nephropathy Completed Mayo Clinic Phase 1 2009-01-01 This pilot study is aimed at demonstrating the effectiveness of ACTH (H.P. Acthar Gel) on the lipid profile and proteinuria in participants with MN. ACTH or adrenocorticotrophin is a hormone produced by the pituitary gland (a gland at the base of your brain) that is involved in stimulating your adrenal glands to secrete a number of steroid products (e.g. cortisol, aldosterone, corticosterone, and others) that are important in keeping you alive. The drug used in this study has been approved by the Food and Drug Administration (FDA) for routine clinical use in the treatment of patients with proteinuria and patients with idiopathic nephrotic syndrome such as idiopathic MN. However, the most adequate dose to use has not been adequately assessed. This is the reason for conducting this research study.
NCT00854750 ↗ Modeling and Treating the Pathophysiology of Demyelination in Multiple Sclerosis Terminated Mallinckrodt Phase 4 2009-05-01 The investigators principal hypothesis is that INO and optic neuritis are objective, quantitative, and reproducible models for corroborating the hypothesis that changes in core body temperature are associated with the reversible and stereotypic decay in axonal conduction and that ACTHAR can serve to prevent such changes. The application of ocular motor and optic nerve measures appears to constitute a useful paradigm to detect and monitor responses to therapeutic strategies that stabilize nerve cell membranes in response to temperature induced decay in axonal conduction mechanisms, with implications on activities of daily life that are dependent upon vision (reading, driving, walking, work performance).
NCT00854750 ↗ Modeling and Treating the Pathophysiology of Demyelination in Multiple Sclerosis Terminated Elliot Frohman Phase 4 2009-05-01 The investigators principal hypothesis is that INO and optic neuritis are objective, quantitative, and reproducible models for corroborating the hypothesis that changes in core body temperature are associated with the reversible and stereotypic decay in axonal conduction and that ACTHAR can serve to prevent such changes. The application of ocular motor and optic nerve measures appears to constitute a useful paradigm to detect and monitor responses to therapeutic strategies that stabilize nerve cell membranes in response to temperature induced decay in axonal conduction mechanisms, with implications on activities of daily life that are dependent upon vision (reading, driving, walking, work performance).
NCT01021540 ↗ Prospective Study Evaluating the Effect of Repository Corticotropin in the Treatment of Various Nephrotic Syndromes Completed Arizona Kidney Disease and Hypertension Center Phase 4 2009-12-01 To determine if H.P. Acthar Gel (repository corticotrophin) has the same anti-proteinuric effects seen with the synthetic ACTH analogue in Europe.
NCT01028287 ↗ Adrenocorticotropic Hormone (ACTH) Treatment of Nephrotic Range Proteinuria in Diabetic Nephropathy (NRDN) Completed Mallinckrodt Phase 4 2009-05-01 This is a prospective open labeled trial examining the efficacy of ACTHar Gel (porcine ACTH) on the level of proteinuria in patients with diabetic nephropathy and nephrotic range proteinuria.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Acthar Gel

Condition Name

Condition Name for Acthar Gel
Intervention Trials
Multiple Sclerosis 8
Sarcoidosis 5
Rheumatoid Arthritis 4
Proteinuria 4
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for Acthar Gel
Intervention Trials
Multiple Sclerosis 14
Sclerosis 14
Kidney Diseases 10
Proteinuria 8
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for Acthar Gel

Trials by Country

Trials by Country for Acthar Gel
Location Trials
United States 249
Mexico 20
Argentina 10
Chile 7
Canada 5
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for Acthar Gel
Location Trials
California 23
New York 22
Texas 18
Florida 16
Ohio 13
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for Acthar Gel

Clinical Trial Phase

Clinical Trial Phase for Acthar Gel
Clinical Trial Phase Trials
Phase 4 44
Phase 3 6
Phase 2/Phase 3 3
[disabled in preview] 14
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for Acthar Gel
Clinical Trial Phase Trials
Completed 32
Unknown status 11
Withdrawn 10
[disabled in preview] 22
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Acthar Gel

Sponsor Name

Sponsor Name for Acthar Gel
Sponsor Trials
Mallinckrodt 55
The Cleveland Clinic 3
University of Colorado, Denver 3
[disabled in preview] 6
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for Acthar Gel
Sponsor Trials
Other 86
Industry 58
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Mallinckrodt
Moodys
Dow
McKesson
Baxter
Colorcon

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.